OBI-992 TROP2 ADC has been granted by TFDA to proceed to Phase I/II human clinical trial

1.Date of occurrence of the event:2024/06/17 2.New drug name or code:OBI-992 TROP2 ADC 3.Indication: OBI-992 is an antibody drug conjugate (ADC) for cancer treatment that is based on TROP2 to target cancer cells. ADC releases a small molecule payload through the specificity of the antibody and directly deploys cytotoxic molecule at the targeted cancer cells. […]